Sunshine Heart to Release First Quarter 2015 Results on May 5, 2015

EDEN PRAIRIE, Minn., April 28, 2015 (GLOBE NEWSWIRE) -- Sunshine Heart, Inc. (Nasdaq: SSH) today announced that its first quarter 2015 results will be released on Tuesday, May 5, 2015, before the open of the stock market. The company will host a conference call and webcast at 9:00 AM ET that morning, during which management will discuss the company's financial results and provide a general business overview.

To access the live webcast, please visit the Investors page of the Sunshine Heart website at http://ir.sunshineheart.com. Alternatively, you may access the live conference call by dialing (877) 303-9826 (U.S.) or (224) 357-2194 (international) and using conference ID 33142990. An audio archive of the webcast will be available following the call at http://ir.sunshineheart.com.

About the C-Pulse® Heart Assist System

The C-Pulse Heart Assist System, or C-Pulse System, an investigational device in the United States, Canada and countries that do not recognize the CE mark approval, utilizes the scientific principles of intra-aortic balloon counter-pulsation applied in an extra-aortic approach to assist the left ventricle by reducing the workload required to pump blood throughout the body, while increasing blood flow to the coronary arteries. Combined, these potential benefits may help sustain the patient's current condition or, in some cases, reverse the heart failure process, thereby potentially preventing the need for later-stage heart failure devices, such as left ventricular assist devices (LVADs), artificial hearts or transplants. It may also provide relief from the symptoms of Class III and ambulatory Class IV heart failure and improve quality of life and cardiac function. Based on the results from our feasibility study, we also believe that some patients treated with our C-Pulse System may be able to stop using the device due to sustained improvement in their conditions as a result of the therapy. Caution: Investigational device, limited by Federal (or United States) Law to Investigational use. About Sunshine® Heart  Sunshine Heart, Inc. (Nasdaq: SSH) is an early-stage medical device company focused on developing, manufacturing and commercializing the C-Pulse System for treatment of Class III and ambulatory Class IV heart failure. Sunshine Heart has completed an approved U.S. Food and Drug Administration (FDA) feasibility clinical study of the C-Pulse System and presented the results in November 2011. In March 2012, the FDA notified the Company that it could move forward with an investigational device exemption (IDE) application. Sunshine Heart received unconditional approval from the FDA in November 2012 to initiate its pivotal study. In July 2012, Sunshine Heart received CE Mark approval for its C-Pulse System in Europe. Sunshine Heart is a Delaware corporation headquartered in Minneapolis with wholly owned subsidiaries in Australia and Ireland. The Company has been listed on the NASDAQ Capital Market since February 2012.

CONTACT: For further information, please contact:

         Investor:

         Candice Knoll
         Blueprint Life Science Group
         T: +1-415-375-3340 Ext. 105

         Claudia Drayton
         Chief Financial Officer
         Sunshine Heart, Inc.
         T: +1-952-345-4200

         Media:

         David Schull
         Russo Partners
         T: +1-212-845-4271

         Christopher Hippolyte
         Russo Partners
         T: + 1-646-942-5634

You May Also Be Interested In

• Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
• Western New England Bancorp, Inc. (WNEB) Tops Q1 EPS by 2c
• Hanmi Financial (HAFC) Misses Q1 EPS by 2c